Synapse Open Synapse
Biology

Theialife’s race to bring a childhood myopia treatment to market

Labiotech.eu · · 1 min read

Our guest today is Thomas Ruggia, CEO of Theialife, a late-stage biotech developing an oral therapy for pediatric myopia derived from a natural caffeine metabolite.

Latest from Labiotech.eu